Next Article in Journal
Opposing Roles of Calcium and Intracellular ATP on Gating of the Purinergic P2X2 Receptor Channel
Next Article in Special Issue
Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy
Previous Article in Journal
Conflicting Roles of Connexin43 in Tumor Invasion and Growth in the Central Nervous System
Previous Article in Special Issue
Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(4), 1160;

An Overview on the Clinical Development of Tau-Based Therapeutics

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Queen Sofia Foundation Alzheimer Center, CIEN Foundation, Carlos III Institute of Health, 28031 Madrid, Spain
Received: 6 March 2018 / Revised: 29 March 2018 / Accepted: 9 April 2018 / Published: 11 April 2018
(This article belongs to the Special Issue Tau Function and Dysfunctional Tauopathies)
Full-Text   |   PDF [295 KB, uploaded 3 May 2018]   |  


Tauopathies such as Alzheimer’s disease (AD), frontotemporal lobar degeneration, or progressive supranuclear palsy constitute a group of brain disorders defined by neurodegeneration and the presence of tau aggregates in the affected brains regions. Tau is a microtubule-associated protein that accumulates in the cytosol under pathological conditions, steering the formation of aggregates or inclusions thought to be involved in the degeneration and neuronal death associated with these diseases. Despite a substantial and unmet medical need for novel, more effective disease-modifying therapies for the treatment of AD and tauopathies, the last couple of decades have seen numerous drug development undertakings primarily focused on β-amyloid, with disappointing results to date. On the other hand, tau-focused approaches have not received much attention until recently, notwithstanding that the presence of extensive tau pathology is fundamental for the disease and tau pathology shows a better correlation with impaired cognitive function than with amyloid pathology in AD patients. The last few years have brought us advances in our comprehension of tau biological functions beyond its well-established role as a microtubule-associated protein, unveiling novel physiological tau functions that may also be involved in pathogenesis and thus provide novel targets for therapeutic intervention. This review describes several emerging, encouraging therapeutic approaches aimed at tackling the underlying causes of tau pathology in AD and other tauopathies that have recently reached the clinical development stage. View Full-Text
Keywords: aggregation; Alzheimer; dementia; drug development; immunotherapy; neurodegeneration; tau; tauopathies; therapy aggregation; Alzheimer; dementia; drug development; immunotherapy; neurodegeneration; tau; tauopathies; therapy

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Medina, M. An Overview on the Clinical Development of Tau-Based Therapeutics. Int. J. Mol. Sci. 2018, 19, 1160.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top